MedWatch

No funding – no company

Danish medtech company Acarix, which will be launching its novel CADScor heart monitoring equipment in the beginning of 2014, has a number of venture capital firms as major investors. But without early funding from a Danish foundation there would not even be a company, says co-founder and former CSO at Coloplast.

Foto: PR

“If we hadn’t received funding from Højteknologifonden (The Danish National Advanced Technology Foundation), there would never have been a company – at least not in relation to this. The funding has been crucial to the establishing of the project.”

Acarix co-founder Peter Samuelsen makes absolutely no bones about it when assessing the significance of the DKK 9m (USD 1.64m) that Højteknologifonden (HTF) posted in the company’s project between 2008 and 2011 – a project that has now resulted in advanced heart monitoring equipment, which in a very fast and simple manner evaluates the risk of coronary artery constriction in heart patients through a built-in microphone, a special patch, and an advanced technique for interpreting the collected signals.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier